Real-World Data on Outcomes in Metastatic Castrate-Resistant Prostate Cancer Patients Treated With Abiraterone or Enzalutamide: A Regional Experience

BACKGROUND: Both abiraterone and enzalutamide have shown to improve overall survival (OS), progression-free survival (PFS) and prostate-specific antigen (PSA) response in patients with metastatic castration-resistant prostate cancer (mCRPC) regardless of previous treatment with chemotherapy (COU-AA3...

Descripción completa

Detalles Bibliográficos
Autores principales: Raju, Rachel, Sahu, Arvind, Klevansky, Myron, Torres, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249852/
https://www.ncbi.nlm.nih.gov/pubmed/34221973
http://dx.doi.org/10.3389/fonc.2021.656146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249852/
https://www.ncbi.nlm.nih.gov/pubmed/34221973
http://dx.doi.org/10.3389/fonc.2021.656146

Ejemplares similares